Last Updated: 14 Nov 2024
Executive Summary
INmune Bio Inc. (INMB) is a clinical-stage immunotherapy company focused on developing treatments for cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company has a market capitalization of $125.5 million and trades on the NASDAQ exchange. INMB's latest stock price is $5.72.
Company Overview
INmune Bio's lead product candidate, INB03, is a monoclonal antibody that targets the CD3 receptor on T cells. INB03 is being evaluated in clinical trials for the treatment of several types of cancer, including melanoma, head and neck cancer, and non-small cell lung cancer. The company also has a pipeline of other preclinical and early-stage clinical candidates.
Fundamental Analysis
INmune Bio reported a net loss of $11.6 million in the first half of 2023, compared to a net loss of $10.3 million in the first half of 2022. The company's revenue for the first half of 2023 was $42,000, compared to $43,000 in the first half of 2022.
INmune Bio's financial performance has been impacted by the COVID-19 pandemic, which has delayed clinical trials and disrupted supply chains. The company's cash and cash equivalents were $46.8 million as of June 30, 2023, which is sufficient to fund operations for the next 12 months.
Technical Analysis
INmune Bio's stock price has been in a downtrend since early 2023. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is below 30, which indicates that the stock is oversold.
Short Term Outlook
INmune Bio's stock price is likely to remain under pressure in the short term. The company is facing several challenges, including the COVID-19 pandemic, delays in clinical trials, and competition from other immunotherapy companies.
Long Term Outlook
INmune Bio's long-term outlook is more positive. The company's lead product candidate, INB03, has the potential to be a blockbuster drug. If INB03 is successful in clinical trials, it could generate significant revenue for the company. INmune Bio also has a pipeline of other promising preclinical and early-stage clinical candidates.
Analyst Recommendations
Two analysts have a "Strong Buy" rating on INmune Bio, and two analysts have a "Buy" rating. The average analyst target price is $19.83, which represents a significant premium to the current stock price.
